Oxford Fetal Medicine Limited 04606670 false 2025-01-01 2025-12-31 2025-12-31 The principal activity of the company is to provide consultancy in obstetrics and feto-maternal medicine Digita Accounts Production Advanced 6.30.9574.0 true true 04606670 2025-01-01 2025-12-31 04606670 2025-12-31 04606670 bus:CompanySecretaryDirector1 1 2025-12-31 04606670 bus:Director2 1 2025-12-31 04606670 core:CurrentFinancialInstruments 2025-12-31 04606670 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 04606670 core:FurnitureFittingsToolsEquipment 2025-12-31 04606670 bus:SmallEntities 2025-01-01 2025-12-31 04606670 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 04606670 bus:FilletedAccounts 2025-01-01 2025-12-31 04606670 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 04606670 bus:RegisteredOffice 2025-01-01 2025-12-31 04606670 bus:CompanySecretaryDirector1 2025-01-01 2025-12-31 04606670 bus:CompanySecretaryDirector1 1 2025-01-01 2025-12-31 04606670 bus:Director2 2025-01-01 2025-12-31 04606670 bus:Director2 1 2025-01-01 2025-12-31 04606670 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 04606670 core:ComputerEquipment 2025-01-01 2025-12-31 04606670 core:FurnitureFittingsToolsEquipment 2025-01-01 2025-12-31 04606670 countries:UnitedKingdom 2025-01-01 2025-12-31 04606670 2024-12-31 04606670 core:FurnitureFittingsToolsEquipment 2024-12-31 04606670 2024-01-01 2024-12-31 04606670 2024-12-31 04606670 bus:CompanySecretaryDirector1 1 2024-12-31 04606670 bus:Director2 1 2024-12-31 04606670 core:CurrentFinancialInstruments 2024-12-31 04606670 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 04606670 core:FurnitureFittingsToolsEquipment 2024-12-31 04606670 bus:CompanySecretaryDirector1 2024-01-01 2024-12-31 04606670 bus:CompanySecretaryDirector1 1 2024-01-01 2024-12-31 04606670 bus:Director2 2024-01-01 2024-12-31 04606670 bus:Director2 1 2024-01-01 2024-12-31 04606670 bus:CompanySecretaryDirector1 1 2023-12-31 04606670 bus:Director2 1 2023-12-31 iso4217:GBP xbrli:pure

Registration number: 04606670

Oxford Fetal Medicine Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2025

 

Oxford Fetal Medicine Limited

Contents

Balance Sheet

1

Notes to the Unaudited Financial Statements

2 to 6

 

Oxford Fetal Medicine Limited

(Registration number: 04606670)
Balance Sheet as at 31 December 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

1,064

1,140

Current assets

 

Debtors

5

24,113

13,395

Cash at bank and in hand

 

139,909

82,300

 

164,022

95,695

Creditors: Amounts falling due within one year

6

(80,003)

(91,643)

Net current assets

 

84,019

4,052

Net assets

 

85,083

5,192

Capital and reserves

 

Called up share capital

7

100

100

Retained earnings

84,983

5,092

Shareholders' funds

 

85,083

5,192

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

•

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 17 September 2026 and signed on its behalf by:
 

.........................................

Dr L Impey
Director

 

Oxford Fetal Medicine Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

1

General information

The company is a private company limited by share capital, incorporated in the United Kingdom.

The address of its registered office is:
Orchard Grove
11 Pixey Close
Yarnton
Kidlington
Oxon
OX5 1FY

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises tax. Tax is recognised in profit or loss.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Oxford Fetal Medicine Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Computer equipment

33% straight line

Fixtures and fittings

25% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised at the transaction price.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Oxford Fetal Medicine Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 3 (2024 - 3).

 

Oxford Fetal Medicine Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 January 2025

4,582

4,582

Additions

739

739

At 31 December 2025

5,321

5,321

Depreciation

At 1 January 2025

3,442

3,442

Charge for the year

815

815

At 31 December 2025

4,257

4,257

Carrying amount

At 31 December 2025

1,064

1,064

At 31 December 2024

1,140

1,140

5

Debtors

Note

2025
£

2024
£

Trade debtors

 

21,750

13,000

Amounts owed by group undertakings and undertakings in which the company has a participating interest

8

2,363

-

Other debtors

 

-

395

 

24,113

13,395

6

Creditors

Creditors: amounts falling due within one year

2025
£

2024
£

Due within one year

Trade creditors

952

985

Taxation and social security

60,259

64,393

Accruals and deferred income

18,639

21,889

Other creditors

153

4,376

80,003

91,643

 

Oxford Fetal Medicine Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

7

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary shares of £1 each

100

100

100

100

       

8

Related party transactions

Transactions with directors

2025

Advances to directors
£

Repayments by director
£

At 31 December 2025
£

Mrs S Impey

Loan

2,363

-

2,363

       
     

Dr L Impey

-

(395)

-

       
     

 

2024

At 1 January 2024
£

Advances to director
£

Repayments by director
£

At 31 December 2024
£

Mrs S Impey

Loan

7,134

-

(7,134)

-

Dr L Impey

-

395

-

395